Omeros Corporation (3O8.F)
| Previous close | 3.4200 |
| Open | 3.4340 |
| Bid | 3.4380 x 33800 |
| Ask | 3.5400 x 33100 |
| Day's range | 3.4340 - 3.4340 |
| 52-week range | 0.9770 - 7.0950 |
| Volume | |
| Avg. volume | 35 |
| Market cap | 201.947M |
| Beta (5Y monthly) | 1.33 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results
SEATTLE, April 01, 2024--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2023, wh
- Business Wire
Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024
SEATTLE, March 27, 2024--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its financial results for the quarter and year ended December 31, 2023, on Monday, April 1, 2024, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.
- Business Wire
Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy
SEATTLE, February 20, 2024--Omeros Corporation (Nasdaq: OMER) today announced the upcoming presentation of a report detailing narsoplimab treatment in nine adult patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). Narsoplimab is Omeros’ investigational antibody targeting MASP-2, the effector enzyme of the lectin pathway of the complement system.
